These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 14603099)

  • 21. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug interactions. Kaletra and atazanavir.
    TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
    [No Abstract]   [Full Text] [Related]  

  • 23. Three new drugs approved by FDA.
    Hoyt G
    Surviv News (Atlanta Ga); 2003; ():13, 20. PubMed ID: 14696579
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA notifications. BMS issues letter about omeprazole.
    AIDS Alert; 2005 Apr; 20(4):45-6. PubMed ID: 15841529
    [No Abstract]   [Full Text] [Related]  

  • 25. Atazanavir: clinical use.
    Bartlett JG
    Hopkins HIV Rep; 2003 Jul; 15(4):3-4. PubMed ID: 14696561
    [No Abstract]   [Full Text] [Related]  

  • 26. Atazanavir for the treatment of human immunodeficiency virus infection.
    Busti AJ; Hall RG; Margolis DM
    Pharmacotherapy; 2004 Dec; 24(12):1732-47. PubMed ID: 15585441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor.
    Modrzejewski KA; Herman RA
    Ann Pharmacother; 2004 Jun; 38(6):1006-14. PubMed ID: 15121999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Revised package insert for atazanavir.
    Sax PE
    AIDS Clin Care; 2008 Mar; 20(3):23. PubMed ID: 18399014
    [No Abstract]   [Full Text] [Related]  

  • 29. First once-daily protease inhibitor.
    FDA Consum; 2003; 37(5):4. PubMed ID: 14666889
    [No Abstract]   [Full Text] [Related]  

  • 30. Warning: do not combine Reyataz and Prilosec.
    AIDS Treat News; 2004; (407-408):5-6. PubMed ID: 15717382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atazanavir (Reyataz).
    Proj Inf Perspect; 2003 Oct; (36):7-10. PubMed ID: 14696568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug interactions. Atazanavir and acid-reducing agents.
    TreatmentUpdate; 2006; 18(3):4. PubMed ID: 17209238
    [No Abstract]   [Full Text] [Related]  

  • 33. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
    Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
    J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial therapy for human immunodeficiency virus: broadening the options.
    Sension M
    HIV Clin Trials; 2004; 5(2):99-111. PubMed ID: 15116286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atazanavir gets FDA Advisory Committee's thumbs-up.
    IAPAC Mon; 2003 Jun; 9(6):120. PubMed ID: 12951939
    [No Abstract]   [Full Text] [Related]  

  • 36. Urolithiasis in HIV-positive patients treated with atazanavir.
    Couzigou C; Daudon M; Meynard JL; Borsa-Lebas F; Higueret D; Escaut L; Zucman D; Liotier JY; Quencez JL; Asselah K; May T; Neau D; Vittecoq D
    Clin Infect Dis; 2007 Oct; 45(8):e105-8. PubMed ID: 17879904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA notifications. Atazanavir capsule label is updated for pediatric patients.
    AIDS Alert; 2008 May; 23(5):59-60. PubMed ID: 18637262
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Avoid PPIs with atazanavir.
    AIDS Clin Care; 2005 Feb; 17(2):18. PubMed ID: 15754453
    [No Abstract]   [Full Text] [Related]  

  • 40. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.
    Rodríguez Nóvoa S; Barreiro P; Rendón A; Barrios A; Corral A; Jiménez-Nacher I; González-Lahoz J; Soriano V
    Clin Infect Dis; 2006 Jan; 42(2):291-5. PubMed ID: 16355344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.